Changing TACTICS in Intermediate HCC: TACE Plus Sorafenib

Gut- United Kingdom

doi 10.1136/gutjnl-2020-320692

Full Text

Abstract

Available in

Date

Authors

Publisher

BMJ

Related search

Sorafenib or Placebo Plus TACE With Doxorubicin-Eluting Beads for Intermediate Stage HCC: The SPACE Trial

Journal of Hepatology
Hepatology
2016English

mRECIST Response Combined With Sorafenib-Related Adverse Events Is Superior to Either Criterion Alone in Predicting Survival in HCC Patients Treated With TACE Plus Sorafenib

International Journal of Cancer
Cancer ResearchOncology
2016English

Multimodality 3D Tumor Segmentation in HCC Patients Treated With TACE

Journal of Vascular and Interventional Radiology
Nuclear MedicineRadiologyCardiologyCardiovascular MedicineImagingMedicine
2015English

The Efficacy of TACE Combined Sorafenib in Advanced Stages Hepatocellullar Carcinoma

BMC Cancer
Cancer ResearchOncologyGenetics
2012English

Immortal Time Bias or Sorafenib Effect in Elderly Patients With HCC?

Hepatology
MedicineHepatology
2017English

Efficacy and Safety of TACE in Combination With Sorafenib for the Treatment of TACE-refractory Advanced Hepatocellular Carcinoma in Chinese Patients: A Retrospective Study

OncoTargets and Therapy
OncologyPharmacology
2017English

Sorafenib for Advanced Hepatocellular Carcinoma (HCC): Impact of Rationing in the United Kingdom.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2010English

Long-Term Survival Analysis of 313 Consecutive HCC Patients Treated With Triple-Drug TACE or Single-Drug TACE With Doxorubicin-Eluting LC Beads

Journal of Vascular and Interventional Radiology
Nuclear MedicineRadiologyCardiologyCardiovascular MedicineImagingMedicine
2017English

Can We Use Sorafenib Targeted Therapy for Advanced Hepatocellular Carcinoma (HCC) Child Pugh B

HPB
HepatologyGastroenterology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy